Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
THALIDOMIDE vs THALOMID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Immunomodulatory and antiangiogenic action: TNF-alpha inhibitor, alters adhesion molecule expression, inhibits angiogenesis via VEGF/FGF inhibition, modulates T-cell co-stimulation and NF-κB activity.
Thalidomide is an immunomodulatory agent with antiangiogenic and anti-inflammatory properties. Its exact mechanism is not fully understood, but it inhibits tumor necrosis factor-alpha (TNF-α) production, modulates cytokine activity, and suppresses angiogenesis by inhibiting basic fibroblast growth factor (b FGF) and vascular endothelial growth factor (VEGF).
Newly diagnosed multiple myeloma (in combination with dexamethasone),Leprosy (erythema nodosum leprosum)
FDA approved: Newly diagnosed multiple myeloma (in combination with dexamethasone),FDA approved: Moderate to severe erythema nodosum leprosum (ENL) in leprosy,Off-label: Crohn's disease,Off-label: Bechet's disease,Off-label: HIV-associated wasting syndrome,Off-label: Recurrent aphthous ulcers
100 mg orally once daily, preferably at bedtime to minimize sedation; maximum dose 400 mg daily for multiple myeloma or erythema nodosum leprosum.
200 mg orally once daily, taken with water preferably at bedtime to reduce sedation; dose may be titrated up to 400 mg daily based on tolerability.
Terminal elimination half-life is approximately 5-7 hours in healthy adults, but may be prolonged to 7-10 hours in patients with renal impairment or advanced age.
Mean terminal elimination half-life is approximately 5-7 hours in healthy adults; may be prolonged to 12-18 hours in patients with hepatic impairment due to decreased metabolism.
Primarily non-enzymatic hydrolysis in plasma; minor CYP2C19-mediated hydroxylation.
Thalidomide is primarily metabolized by spontaneous hydrolysis in plasma and tissues, not by cytochrome P450 enzymes. Minor metabolism involves hydroxylation and conjugation.
Thalidomide is primarily eliminated by nonenzymatic hydrolysis in plasma and tissues; renal excretion accounts for <1% of unchanged drug; metabolites are excreted renally (~90%) and fecally (~10%).
Primarily renal: >80% of absorbed dose excreted unchanged in urine. Minor fecal elimination (<15%). No significant biliary excretion.
Approximately 55-65% bound to albumin and alpha-1-acid glycoprotein.
Approximately 55-66% bound to serum albumin.
Volume of distribution is approximately 1.2 L/kg (range 0.8-1.5 L/kg), indicating extensive distribution into body tissues.
Apparent Vd is 0.7-1.2 L/kg, suggesting distribution into total body water with some tissue binding.
Oral bioavailability is approximately 90-100% (absolute bioavailability).
Oral bioavailability is >90% with minimal first-pass metabolism.
No dosage adjustment required for renal impairment. Thalidomide is minimally renally excreted; however, use with caution in severe renal impairment (Cr Cl <30 m L/min) due to limited data.
For GFR 30-60 m L/min: reduce dose by 50%; for GFR <30 m L/min or dialysis: administer 100 mg once daily; for severe renal impairment, consider alternative therapy.
Child-Pugh Class A: 100 mg daily. Child-Pugh Class B: Reduce to 50 mg daily or 100 mg every other day. Child-Pugh Class C: Not recommended due to lack of safety data.
Child-Pugh Class A: no adjustment; Child-Pugh Class B or C: use with caution, consider dose reduction; limited data for severe hepatic impairment.
Not approved for use in children; safety and efficacy not established. In investigational settings, 2-5 mg/kg/day orally divided every 12 hours, with a maximum of 100 mg/day.
Not recommended for use in children <18 years due to lack of safety and efficacy data; in clinical trials for specific conditions (e.g., recurrent brain tumors), doses of 3-6 mg/kg/day have been used, but not approved.
No specific dose adjustment, but start at low end of dosing range (50-100 mg daily) due to increased risk of sedation, constipation, and peripheral neuropathy. Monitor renal function, though no dose adjustment required.
Start at lower end of dosing range (e.g., 100 mg daily) due to increased sensitivity to sedation and thromboembolic risk; monitor renal function as elderly often have decreased GFR.
THALIDOMIDE IS CONTRAINDICATED IN PREGNANCY (CATEGORY X). Severe birth defects (phocomelia, other fetal anomalies) and fetal death. Must not be used by women who are pregnant or may become pregnant. Also contraindicated in sexually active women of childbearing potential unless using two reliable forms of contraception. Male patients must use latex condom during sexual contact with pregnant or childbearing-potential women. [See REMS program]
THALOMID is contraindicated in pregnancy due to severe life-threatening birth defects. It must never be used by females who are pregnant or could become pregnant. If thalidomide is used during pregnancy, it can cause severe birth defects or death of the fetus. Additionally, females of reproductive potential must use two effective forms of contraception or abstain from heterosexual intercourse for at least 4 weeks before starting therapy, during therapy, and for 4 weeks after discontinuing therapy.
Thromboembolism (DVT/PE) - increased risk with concurrent dexamethasone. Severe peripheral neuropathy (monitor for paresthesias). Neutropenia, thrombocytopenia. Dizziness, somnolence. Hypersensitivity reactions (angioedema, Stevens-Johnson syndrome). Bradycardia, syncope. Increased LFTs. Seizures. Amyloid deposition. Angioedema. Increases risk of hepatotoxicity. Use in renal/hepatic impairment with caution.
Venous thromboembolic events (VTE) – increased risk, especially when combined with dexamethasone,Fetal exposure – requires patient enrollment in the THALOMID REMS program,Hypersensitivity reactions – including rash, Stevens-Johnson syndrome,Peripheral neuropathy – may be irreversible, monitor for symptoms,Somnolence and dizziness – may impair ability to drive or operate machinery,Syncope and bradycardia – may occur, especially in elderly,Hepatotoxicity – monitor liver function tests,Hematologic toxicity – neutropenia and thrombocytopenia,Seizures – use with caution in patients with history of seizures
Pregnancy (Category X) - fetal toxicity. Women of childbearing potential not using two forms of contraception. Men not using latex condom. Hypersensitivity to thalidomide. Use with drugs that cause peripheral neuropathy. Severe neutropenia (ANC < 750/μL).
Pregnancy or women of childbearing potential not using two forms of contraception,Hypersensitivity to thalidomide or any component of the formulation,Use in females who are breastfeeding (contraindicated due to potential harm to infant)
Avoid grapefruit juice (may increase exposure). No specific food restrictions otherwise.
Take with water on an empty stomach (at least 1 hour before or 2 hours after meals). Avoid grapefruit juice, alcohol, and high-fat meals as they may alter absorption and increase risk of side effects.
Thalidomide is contraindicated in pregnancy. First trimester exposure causes severe limb defects (phocomelia, amelia), ear anomalies, ocular defects, and cardiac malformations in up to 50% of exposed fetuses. Second and third trimester exposure risks fetal growth restriction and neurodevelopmental effects. No safe trimester exists.
Thalidomide is a known human teratogen. In the first trimester, exposure is associated with a high risk of severe birth defects including limb reduction defects, congenital heart disease, and anotia. No safe gestational trimester exists; contraindicated in pregnancy.
Thalidomide is excreted in human milk; M/P ratio is approximately 0.5. Breastfeeding is contraindicated due to potential adverse effects in the infant, including sedation and neutropenia.
Excretion into breast milk unknown. Due to potential for adverse effects in the nursing infant, breastfeeding is contraindicated. M/P ratio not available.
No dose adjustment studies in pregnancy exist because thalidomide is contraindicated. Pharmacokinetic changes in pregnancy (e.g., increased clearance, altered distribution) are expected but dose adjustments should not be attempted; alternative therapy must be used.
Contraindicated in pregnancy; no dose adjustments applicable because thalidomide is absolutely contraindicated during pregnancy.
Strict REMS program required due to teratogenicity; screen for pregnancy before and during therapy. Monitor for thromboembolism, neuropathy, and bradycardia. Dose reduction needed in renal impairment. Can cause tumor lysis syndrome in multiple myeloma.
Thalomid (thalidomide) is a potent teratogen requiring strict pregnancy prevention. It has immunomodulatory, anti-inflammatory, and anti-angiogenic properties. Used primarily for erythema nodosum leprosum (ENL) and multiple myeloma. Monitor for thromboembolic events, peripheral neuropathy, and bradycardia. Dose adjustment needed for hepatic impairment. Ensure patient enrollment in THALOMID REMS program.
Never use during pregnancy – can cause severe birth defects.,Women must use two reliable contraceptives and undergo monthly pregnancy tests.,Men must use condoms during sexual activity with a pregnant woman or a woman who could become pregnant.,Avoid blood donation while on therapy and for 4 weeks after stopping.,Report numbness, tingling, drowsiness, or rash immediately.
Thalidomide can cause severe birth defects; use two forms of contraception during treatment and for 4 weeks after stopping.,Do not take during pregnancy or if planning to become pregnant; male patients must use condoms during sexual activity.,Report any numbness, tingling, or pain in hands/feet immediately.,Seek emergency care for signs of blood clots: chest pain, shortness of breath, leg swelling, or vision changes.,Avoid alcohol and grapefruit juice as they may increase side effects.,Do not donate blood or sperm while on therapy and for 4 weeks after discontinuation.
"Thalidomide, a sedative-hypnotic with central nervous system (CNS) depressant properties, can additively enhance the CNS-depressant effects of tiagabine, an anticonvulsant that potentiates GABAergic neurotransmission. This combination increases the risk of excessive sedation, dizziness, psychomotor impairment, and respiratory depression. Patients may experience compounded neurological effects, leading to reduced alertness and increased fall risk, particularly during initiation or dose escalation."
"Thalidomide, a known central nervous system depressant, can potentiate the sedative effects of fluticasone propionate, particularly when administered at high doses or via inhalation. This additive CNS depression may lead to increased sedation, dizziness, and impairment of cognitive or motor function, posing risks for falls or accidents. Patients should be warned against driving or operating heavy machinery until the combined effects are known."
"Thalidomide, an immunomodulatory agent, may antagonize the laxative effect of picosulfuric acid by reducing gastrointestinal motility through its anticholinergic-like properties and potential to cause constipation. This interaction could lead to decreased effectiveness of picosulfuric acid in promoting bowel evacuation, potentially resulting in inadequate bowel preparation for procedures or incomplete relief of constipation. Clinically, patients may experience reduced stool output or delayed onset of action, requiring alternative or additional laxative therapy."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about THALIDOMIDE vs THALOMID, answered by our medical review team.
THALIDOMIDE is a Immunomodulatory Agent that works by Immunomodulatory and antiangiogenic action: TNF-alpha inhibitor, alters adhesion molecule expression, inhibits angiogenesis via VEGF/FGF inhibition, modulates T-cell co-stimulation and NF-κB activity.. THALOMID is a Immunomodulatory Agent that works by Thalidomide is an immunomodulatory agent with antiangiogenic and anti-inflammatory properties. Its exact mechanism is not fully understood, but it inhibits tumor necrosis factor-alpha (TNF-α) production, modulates cytokine activity, and suppresses angiogenesis by inhibiting basic fibroblast growth factor (b FGF) and vascular endothelial growth factor (VEGF).. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between THALIDOMIDE and THALOMID depend on the specific clinical indication. These are both Immunomodulatory Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of THALIDOMIDE is: 100 mg orally once daily, preferably at bedtime to minimize sedation; maximum dose 400 mg daily for multiple myeloma or erythema nodosum leprosum.. The standard adult dose of THALOMID is: 200 mg orally once daily, taken with water preferably at bedtime to reduce sedation; dose may be titrated up to 400 mg daily based on tolerability.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between THALIDOMIDE and THALOMID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. THALIDOMIDE is classified as Category D/X. Thalidomide is contraindicated in pregnancy. First trimester exposure causes severe limb defects (phocomelia, amelia), ear anomalies, ocular defects, and cardiac malformations in u. THALOMID is classified as Category C. Thalidomide is a known human teratogen. In the first trimester, exposure is associated with a high risk of severe birth defects including limb reduction defects, congenital heart d. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.